Nachrichten zur Viatris Inc. Aktie

ROUNDUP: Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend

CANONSBURG (dpa-AFX) - While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its…

Form 8-K Viatris Inc For: Aug 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris, Mapi Pharma: FDA Accepts For Review NDA For GA Depot To Treat RMS

CANONSBURG (dpa-AFX) - Healthcare company Viatris Inc. (VTRS) and Mapi Pharma Ltd., a late-stage clinical development pharmaceutical company, announced Monday…

Viatris Inc. Q2 Profit Drops

CANONSBURG (dpa-AFX) - Viatris Inc. (VTRS) announced earnings for second quarter that decreased from last yearThe companys earnings totaled $264.0…

Viatris beats Q2 top and bottom line estimates; reaffirms FY23 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP…

Viatris hopes for Q2 earnings beats amid negative YTD return

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years

If youre patient and consistent, it wont be too hard to build up a revenue stream....…

Viatris, Kindeva launch Breyna to treat asthma and COPD patients

The drug-device combination product, Breyna is claimed to be the first US Food and Drug Administration (FDA)-approved generic version of…

Viatris Announces Launch of Breyna Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People With Asthma and Chronic Obstructive Pulmonary Disease, in Partnership With Kindeva

PITTSBURGH, PA and WOODBURY, MN / ACCESSWIRE / July 31, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, and…

Viatris 2022 Sustainability Report: Partnering To End Tuberculosis

NORTHAMPTON, MA / ACCESSWIRE / July 24, 2023 / Tuberculosis (TB) is the second deadliest infectious disease, causing 1.5 million…

Viatris Stock: Bull vs. Bear

Viatris shares have declined in the double digits over the past few years....…

Better Pharma Buy: Viatris vs. Pfizer

Both stocks look cheap today....…

Viatris 2022 Sustainability Report: Reducing the Burden of NCDs

NORTHAMPTON, MA / ACCESSWIRE / July 18, 2023 / Noncommunicable diseases (NCDs) cause approximately 41 million deaths each year globally…

Better High-Yield Dividend Stock: Altria or Viatris?

Which of these top income stocks is the better buy right now?...…

3 Reasons to Buy Viatris Stock, and 1 Reason to Sell

This drugmaker could be a great stock to own over the coming years....…

Viatris 2022 Sustainability Report: Responding to Continued COVID-19 Pandemic Needs

NORTHAMPTON, MA / ACCESSWIRE / July 12, 2023 / ViatrisOur work to respond to emergent needs from the COVID-19 pandemic…

Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?

There are a few trends moving in the right direction, and they could easily add up....…

Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023

PITTSBURGH, June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on…

Viatris (VTRS) Flat As Market Gains: What You Should Know

Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session....…

Barclays Downgrades Viatris

Barclays has downgraded its outlook for Viatris to Underweight....…

Viatris cut to Underweight at Barclays citing a “show-me” story

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris 2022 Sustainability Report: Advancing Progress for HIV Prevention, Diagnosis and Treatment

NORTHAMPTON, MA / ACCESSWIRE / June 15, 2023 / ViatrisAs a leading global supplier of ARVs used to prevent and…

Viatris 2022 Sustainability Report: Our Initial Access and Health Goals

NORTHAMPTON, MA / ACCESSWIRE / June 12, 2023 / At Viatris, we believe that access is incredibly personal. It is…

Advancing Sustainability at Viatris

NORTHAMPTON, MA / ACCESSWIRE / June 8, 2023 / ViatrisTo make progress on our mission and successfully deliver on our…

Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

Viatris: Smart Solutions To Reduce Packaging Waste

NORTHAMPTON, MA / ACCESSWIRE / June 5, 2023 / As part of our work to reduce our environmental impact while…

InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan

May 31, 2023 – InDex Pharmaceuticals Holding AB (publ) (“InDex”) today announced that a license agreement has been signed with…

Viatris CEO Scott A. Smith: Delivering on Our Mission for Stakeholders

NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / ViatrisBy Scott A. Smith, Chief Executive Officer, ViatrisSince first joining the…

XETR : DIVIDEND/INTEREST INFORMATION - 23.05.2023 - US92556V1061

Das Instrument VIA US92556V1061 VIATRIS INC. O.N. EQUITY wird ex Dividende/Zinsen gehandelt am 23.05.2023 The instrument VIA US92556V1061 VIATRIS INC.…

Viatris goes ex dividend tomorrow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Viatris Inc For: May 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year

Coury will serve in this new role until the end of 2025 PITTSBURGH, May 22, 2023 /PRNewswire/ -- Viatris Inc.…

Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine

PITTSBURGH, PA / ACCESSWIRE / May 16, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today published its 2022…

Viatris: Partnership Provides Access to Education, Role Models for Children in India

NORTHAMPTON, MA / ACCESSWIRE / May 9, 2023 / ViatrisLike many of the other children born in the Singareni community…

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 20221 Q1 2023 YUPELRI…

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling…

Viatris reaffirms 2023 sales forecast on strong demand for newer drugs

...May 8 (Reuters) - Viatris Inc reaffirmed its full-year revenue......…

Viatris (VTRS) Tops Q1 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 13.04% and 1.75%, respectively, for the quarter ended March 2023. Do the…

Form 8-K Viatris Inc For: May 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

ROUNDUP: Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend

CANONSBURG (dpa-AFX) - While reporting financial results for the first quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its…

Viatris reports Q1 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris expects return to growth as Q1 topline contracts 11%

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris Inc. Q1 Income Falls

CANONSBURG (dpa-AFX) - Viatris Inc. (Y) released a profit for first quarter that decreased from last yearThe companys earnings came…

Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Reports Total Revenues of $3.73 billion; U.S. GAAP Net Earnings of $225 million; Adjusted EBITDA of $1.34 billion; U.S. GAAP…

dpa-AFX ProFeed